Fusidic acid
Synonym :
Sodium Fusidate
Mechanism :
Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops but may also be given systemically as tablets or injections.
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.
Indication :
- Staphylococcal skin infections.
Contraindications :
Hypersensitivity
Dosing :
Topical:
Apply to affected area 2-3 times daily.
Adverse Effect :
Hypersensitivity reactions such as burning, mild irritation, redness or swelling to cream. Loss of appetite, abdominal or stomach pain, increase in bowel movements, nausea, loose stools.
Interaction :
Amprenavir: The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid.
Atorvastatin: Increased risk of myopathy/rhabdomyolysis.
Fosamprenavir: The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid.
Indinavir: Indinavir may increase the effect and toxicity of fusidic acid.
Nelfinavir: The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid.
Penicillin V: Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid.
Ritonavir: The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.
Saquinavir: The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
Simvastatin: Increased risk of myopathy/rhabdomyolysis.
Ticarcillin: Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
Tipranavir: Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxicity of both agents.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
20-50 | Dose as in normal renal function |
10-20 | Dose as in normal renal function |
<10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
CAPD | Not dialysed. Dose as in normal renal function |
HD | Not dialysed. Dose as in normal renal function |
HDF/High flux | Unknown dialysability. Dose as in normal renal function |
CAV/VVHD | Not dialysed. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended.